Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- risks factors
研究概览
简要总结
This is a single center collection of discarded biological samples and electronic medical review (EMR) data on patients who are hospitalized with clostridium difficile infections and treated with Fidaxomicin
详细描述
This single site study will be a clinical research data base of patients hospitalized and diagnosed with Clostridium difficile infection (CDI), treated with Fidaxomicin and willing to allow us to collect discard biological samples for testing and analysis in the investigators lab. An additional blood sample will be obtained if a clinically indicated bronchoscopy is performed as to measure the amount of medication in the BAL. We will also complete a medical record review will also occur.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years of age
- •Currently an inpatient at UPMC Presbyterian
- •Diagnosed with an CDI
- •Being treated with Fidaxomicin
排除标准
- •not meeting entry criteria
研究组 & 干预措施
clostridium difficile infection (CDI)
This is a pilot project. Data from electronic medical records will be collected on all patients diagnosed with clostridium difficile infection and who are receiving fidaxomicin as part of their treatment. A total of 50 patients will be enrolled
干预措施: Fidaxomicin (Drug)
结局指标
主要结局
risks factors
时间窗: "1 year"
Incidence of death as indicated in medical record
次要结局
- CDI episodes("1 year")